We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]
We were privileged to hear visionary insights during Mike Ward’s fascinating fireside chat with Werner Lanthaler, CEO of Evotec. In the discussion, he asked Werner to share his views about the sector and big macro issues, as well as what it takes to build a biotech. This is what we learned: The teenage Werner wanted […]
alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs pre-implantation (p<0.001) 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001) alfapump primary safety endpoint data in line with expectations On track to file Pre-Market […]
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]
Denmark’s first fully functional generally applicable quantum computer will be available in 2034. This is the objective of the ambitious Novo Nordisk Foundation Quantum Computing Programme that is being launched in collaboration with the University of Copenhagen. Quantum computers will help in developing new medicine and provide new insight into climate change and the green […]
